Companies / BOC Sciences / Polatuzumab
BOC Sciences

Polatuzumab | BOC Sciences

Polatuzumab is a monoclonal antibody directed against CD79b, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab can be used in the synthesis of polatuzumab vedotin, an ADC indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.